The Intratumoral Bacterial Metataxonomic Signature of Hepatocellular Carcinoma.
Huang JH, Wang J, Chai XQ, Li ZC, Jiang YH, Li J, Liu X, Fan J, Cai JB, Liu F.
Microbiol Spectr. 2022 Oct 26;10(5):e0098322. doi: 10.1128/spectrum.00983-22. Epub 2022 Sep 29.
In Situ Vaccination as a Strategy to Modulate the Immune Microenvironment of Hepatocellular Carcinoma.
Lurje I, Werner W, Mohr R, Roderburg C, Tacke F, Hammerich L.
Front Immunol. 2021 May 7;12:650486. doi: 10.3389/fimmu.2021.650486. eCollection 2021.
m(6)A-mediated lnc-OXAR promotes oxaliplatin resistance by enhancing Ku70 stability in non-alcoholic steatohepatitis-related hepatocellular carcinoma.
Lin Z, Huang Z, Qiu J, Shi Y, Zuo D, Qiu Z, He W, Niu Y, Yuan Y, Li B.
J Exp Clin Cancer Res. 2024 Jul 25;43(1):206. doi: 10.1186/s13046-024-03134-4.
In situ Thermal-Responsive Magnetic Hydrogel for Multidisciplinary Therapy of Hepatocellular Carcinoma.
Yan X, Sun T, Song Y, Peng W, Xu Y, Luo G, Li M, Chen S, Fang WW, Dong L, Xuan S, He T, Cao B, Lu Y.
Nano Lett. 2022 Mar 23;22(6):2251-2260. doi: 10.1021/acs.nanolett.1c04413. Epub 2022 Mar 7.
M6A-mediated upregulation of LINC00958 increases lipogenesis and acts as a nanotherapeutic target in hepatocellular carcinoma.
Zuo X, Chen Z, Gao W, Zhang Y, Wang J, Wang J, Cao M, Cai J, Wu J, Wang X.
J Hematol Oncol. 2020 Jan 8;13(1):5. doi: 10.1186/s13045-019-0839-x.
A distinct microbiota signature precedes the clinical diagnosis of hepatocellular carcinoma.
Yang J, He Q, Lu F, Chen K, Ni Z, Wang H, Zhou C, Zhang Y, Chen B, Bo Z, Li J, Yu H, Wang Y, Chen G.
Gut Microbes. 2023 Jan-Dec;15(1):2201159. doi: 10.1080/19490976.2023.2201159.
Intratumoural microbiome can predict the prognosis of hepatocellular carcinoma after surgery.
Sun L, Ke X, Guan A, Jin B, Qu J, Wang Y, Xu X, Li C, Sun H, Xu H, Xu G, Sang X, Feng Y, Sun Y, Yang H, Mao Y.
Clin Transl Med. 2023 Jul;13(7):e1331. doi: 10.1002/ctm2.1331.
CircTTC13 promotes sorafenib resistance in hepatocellular carcinoma through the inhibition of ferroptosis by targeting the miR-513a-5p/SLC7A11 axis.
Zhang Y, Yao R, Li M, Fang C, Feng K, Chen X, Wang J, Luo R, Shi H, Chen X, Zhao X, Huang H, Liu S, Yin B, Zhong C.
Mol Cancer. 2025 Jan 27;24(1):32. doi: 10.1186/s12943-024-02224-3.
MiR-126 in Hepatocellular Carcinoma and Cholangiocellular Carcinoma: A Reappraisal with an in situ Detection of miR-126.
Zailaie SA, Sergi CM.
Ann Clin Lab Sci. 2022 Jan;52(1):73-85.
BIRC2 blockade facilitates immunotherapy of hepatocellular carcinoma.
Fu L, Li S, Mei J, Li Z, Yang X, Zheng C, Li N, Lin Y, Cao C, Liu L, Huang L, Shen X, Huang Y, Yun J.
Mol Cancer. 2025 Apr 14;24(1):113. doi: 10.1186/s12943-025-02319-5.
